2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07A.03 Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study

P2.07A.03 Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study

Back to course

Pdf Summary

The CReGYT-01 EGFR study assesses the prognostic impact of uncommon EGFR mutations in patients with completely resected lung adenocarcinoma. Conducted as a multicenter retrospective observational study in Japan, the research delves into the survival outcomes for such patients, who exhibit rarer EGFR mutations like G719X, S768I, L861Q, de novo T790M, and ex20ins. These mutations are notably less responsive to EGFR-TKIs (tyrosine kinase inhibitors) than the more common mutations, making their impact on prognosis and treatment outcomes less well understood.<br /><br />Patient characteristics were analyzed using statistical tests such as the Wilcoxon test and Fisher’s exact test. Recurrence-free survival (RFS), overall survival (OS), and survival after recurrence were evaluated via Kaplan–Meier survival curves, assessed through the log-rank test, and analyzed using both univariable and multivariable Cox proportional hazards regression analyses.<br /><br />The study found that uncommon EGFR mutations made up 11.9% of the cases examined. While the RFS showed no significant differences across all patients (P = 0.868), poorer overall survival (OS) was noted in patients with uncommon mutations, particularly in stages II-III lung adenocarcinoma (P = 0.064 and P = 0.007, respectively). Furthermore, patients harboring these uncommon mutations exhibited reduced survival after recurrence when treated with EGFR-TKIs, with significance highlighted (P = 0.001).<br /><br />The study concludes there is a critical need for the advancement of both post-recurrent and perioperative management strategies to improve treatment outcomes for patients with these uncommon mutations, underscoring the challenges faced due to their lessened sensitivity to standard EGFR-TKI therapies.

Asset Subtitle

Kazuki Hayasaka

Meta Tag

Speaker Kazuki Hayasaka

Topic Early-Stage NSCLC

Keywords

CReGYT-01 EGFR study

uncommon EGFR mutations

lung adenocarcinoma

prognostic impact

G719X

S768I

L861Q

de novo T790M

ex20ins

EGFR-TKIs resistance